In the first quarter of 2026, the market reached 4.94 billion roubles, up 6.24% from a year earlier, according to analysts at Headway Company. By comparison, the market stood at 4.65 billion roubles in the same period of 2025 and 4.8 billion roubles in 2024. After a slight dip last year, the market has returned to growth.
AstraZeneca’s Fasenra remains the market leader with sales of 636.6 million roubles, up 15.7%, giving it a 12.88% share. In second place is Boehringer Ingelheim’s Spiriva Respimat, which grew 59.4% to 439.7 million roubles, with one of the highest pack volumes – 227,170 packs. Third is Genolar (the first domestic biosimilar of original drug Xolair) from Generium, with 380.9 million roubles, up 1.7%.
The most notable shift in demand was the sharp rise in sales of Tezspire (AstraZeneca and Amgen), which surged 495.6% to 340.6 million roubles, giving the brand a 6.89% market share. Despite relatively small pack sales (5,860 packs), it entered the top four by revenue.
Analysts also highlighted Trimbo from Italy’s Chiesi Farmaceutici, used for severe COPD and bronchial asthma. It ranked ninth among the top ten brands but posted explosive growth of 2,467.6%, reflecting a rapid shift by physicians toward innovative treatment regimens.
At the same time, several drugs showed negative trends. Formisonide fell 27.2% to 329.1 million roubles, while Respisalf Air dropped 3.8% to 229.6 million roubles, despite high pack sales volumes.
Among distributors, FC Grand Capital led with 542.9 million roubles, followed by RB Trade with 533 million roubles. Lantset, Remedium Pharm and R-Pharm rounded out the top five.
Analysts noted that after growth in 2023–2024, the market entered a stabilisation phase, but early 2026 is again showing positive momentum. Government procurement in the segment totalled 16.39 billion roubles (+15.8%) in 2023 and 20.67 billion roubles (+26.1%) in 2024, followed by 20.93 billion roubles (+1.3%) in 2025.
According to the World Health Organization, more than 260 million people worldwide suffer from asthma. In Russia, the actual number of patients may reach 10 million, according to Sergei Avdeev, chief pulmonologist of Russia’s Health Ministry, with a significant portion of cases remaining undiagnosed.
COPD has a significant impact on Russia’s economy and life expectancy, the All‑Russian Patient Union said. The organisation estimates the annual economic damage from the disease at 500 billion roubles. Further reduction of the disease burden requires elevating the issue to the government level, with subsequent institutionalisation of measures and oversight of their implementation, the Union believes.
